Mapping the safety profile of biologicals: A disproportionality analysis using the who adverse drug reaction database, vigibase

Drug Safety

Volumn 33, Issue 10, 2010, Pages 865-878

  Giezen, Thijs J ^a,b   Mantel Teeuwisse, Aukje K ^a,b   Meyboom, Ronald H B ^a,c   Straus, Sabine M J M ^b   Leufkens, Hubert G M ^a,b   Egberts, Toine C G ^a,d  

^a UTRECHT UNIVERSITY   (Netherlands)

^b MEDICINES EVALUATION BOARD   (Netherlands)

^c UPPSALA MONITORING CENTRE   (Sweden)

^d UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

Adalimumab, adverse reactions; Adverse reaction monitoring; Cytokines, adverse reactions; Enzymes, adverse reactions; Etanercept, adverse reactions; Growth factors, adverse reactions; Infliximab, adverse reactions; Interferon, adverse reactions; Interferon beta 1a, adverse reactions; Monoclonal antibodies, adverse reactions; Postmarketing surveillance; Teriparatide, adverse reactions

Indexed keywords

ADALIMUMAB; ANTIBODY; BETA1A INTERFERON; BIOLOGICAL PRODUCT; CYTOKINE; ENZYME; ETANERCEPT; GROWTH FACTOR; HORMONE; INFLIXIMAB; INTERFERON; PARATHYROID HORMONE[1-34]; RECEPTOR;

ADULT; ADVERSE DRUG REACTION; ARTICLE; BENIGN TUMOR; BLOOD DISEASE; BREAST DISEASE; CONGENITAL DISORDER; CONNECTIVE TISSUE DISEASE; DATA BASE; DRUG MONITORING; DRUG SAFETY; ENDOCRINE DISEASE; EYE DISEASE; FAMILIAL DISEASE; FEMALE; GASTROINTESTINAL DISEASE; GENETIC DISORDER; GENITAL SYSTEM DISEASE; HEART DISEASE; HEPATOBILIARY DISEASE; HUMAN; IMMUNOPATHOLOGY; INFECTION; INFESTATION; INJURY; INNER EAR DISEASE; INTOXICATION; KIDNEY DISEASE; LYMPHATIC SYSTEM DISEASE; MAJOR CLINICAL STUDY; MALE; MALIGNANT NEOPLASTIC DISEASE; MEDIASTINUM DISEASE; MENTAL DISEASE; METABOLIC DISORDER; MUSCULOSKELETAL DISEASE; NEUROLOGIC DISEASE; NUTRITIONAL DISORDER; PERINATAL MORBIDITY; PREGNANCY DISORDER; PRIORITY JOURNAL; PUERPERIUM; RESPIRATORY TRACT DISEASE; SKIN DISEASE; THORAX DISEASE; URINARY TRACT DISEASE; UROGENITAL TRACT DISEASE; VASCULAR DISEASE;

ADULT; ADVERSE DRUG REACTION REPORTING SYSTEMS; BIOLOGICAL PRODUCTS; DATABASES, FACTUAL; FEMALE; HUMANS; IMMUNOLOGIC FACTORS; MALE; MIDDLE AGED; PHARMACEUTICAL PREPARATIONS; WORLD HEALTH ORGANIZATION;

EID: 77956334120     PISSN: 01145916     EISSN: 11791942     Source Type: Journal    
DOI: 10.2165/11538330-000000000-00000     Document Type: Article

References (35)

1. Crommelin DJ, Storm G, Verrijk R, et al. Shifting paradigms: biopharmaceuticals versus low molecular weight drugs. Int J Pharm 2003 Nov; 266 (1-2): 3-16
2. Schellekens H. How similar do biosimilars need to be? Nat Biotechnol 2004 Nov; 22 (11): 1357-1359
3. Brennan FR, Shaw L, Wing MG, et al. Preclinical safety testing of biotechnology-derived pharmaceuticals: understanding the issues and addressing the challenges. Mol Biotechnol 2004 May; 27 (1): 59-74
4. Giezen TJ,Mantel-Teeuwisse AK, Leufkens HG. Pharmacovigilance of biopharmaceuticals: challenges remain. Drug Saf 2009 Oct; 32 (10): 811-817
5. Giezen TJ, Mantel-Teeuwisse AK, Straus SMJM, et al. Evaluation of post-authorization safety studies in the first cohort of EU risk management plans at time of regulatory approval. Drug Saf 2009 Dec; 32 (12): 1175-1187
6. Stricker BH, Psaty BM. Detection, verification, and quantification of adverse drug reactions. BMJ 2004 Jul; 329 (7456): 44-47
7. Giezen TJ, Mantel-Teeuwisse AK, Straus SM, et al. JAMA 2008 Oct; 300 (16): 1887-1896
8. Lasser KE, Allen PD, Woolhandler SJ, et al. Timing of new black box warnings and withdrawals for prescription medications. JAMA 2002 May; 287 (17): 2215-2220
9. Bakke OM, Manocchia M, de Abajo F, et al. Drug safety discontinuations in the United Kingdom, the United States, and Spain from 1974 through 1993: a regulatory perspective. Clin Pharmacol Ther 1995 Jul; 58 (1): 108-17
10. Meyboom RHB, Gribnau FWJ, Hekster YA, et al. Characteristics of topics in pharmacovigilance in The Netherlands. Clin Drug Invest 1996; 12: 207-219
11. European Commission. Volume 9A of the rules governing medicinal products in the European Union: guideline on pharmacovigilance for medicinal products for human use [online]. Available from URL: http://ec.europa.eu/enterprise/ pharmaceuticals/eudralex/vol-9/pdf/vol9a-09-2008.pdf [Accessed 2009 Dec 22]
12. Hazell L, Shakir SA. Under-reporting of adverse drug reactions: a systematic review. Drug Saf 2006 May; 29 (5): 385-396
13. Meyboom RH, Egberts AC, Gribnau FW, et al. Pharmacovigilance in perspective. Drug Saf 1999 Dec; 21 (6): 429-447
14. Keane J, Gershon S,Wise RP, et al. Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N Engl J Med 2001 Oct; 345 (15): 1098-1104
15. Jacobs JW, Creemers MC, van Agtmael MA, et al. TNF-blocking drugs and infection: recommendations for daily practice. Ned Tijdschr Geneeskd 2007 Mar; 151 (10): 588-593
16. Martin-Mola E, Balsa A. Infectious complications of biologic agents. Rheum Dis Clin North Am 2009 Feb; 35 (1): 183-199
17. Nijsten T, Spuls PI, Naldi L, et al. The misperception that clinical trial data reflect long-term drug safety. Arch Dermatol 2009 Sep; 145 (9): 1037-1039
18. Uppsala Monitoring Centre [online]. Available from URL: http://www.who-umc.org [Accessed 2010 May 4]
19. Commission of European Communities. Commission Directive 2003/63/EC of 25 June 2003 amending Directive 2001/83/EC of the European Parliament and of the Council on the Community code relating to medicinal products for human use [online]. Available from URL: http://eur-lex.europa.eu/LexUriServ/LexUriServ.do? uri=OJ:L:2003:159:0046:0094:EN:PDF [Accessed 2010 May 4]
20. National Cancer Institute [online]. Available from URL: http://www.cancer.gov [Accessed 2010 May 4]
21. Pichler WJ. Adverse side-effects to biological agents. Allergy 2006 Aug; 61 (8): 912-920
22. Bate A, Evans SJ. Quantitative signal detection using spontaneous ADR reporting. Pharmacoepidemiol Drug Saf 2009 Jun; 18 (6): 427-436
23. Evans SJW, Waller PC, Davis S. Use of proportional reporting ratios (PRR) for signal generation from spontaneous adverse drug reaction reports. Pharmacoepidemiol Drug Saf 2001 Oct-Nov; 10 (6): 483-6
24. Huggett B, Hodgson J, Lahteenmaki R. Public biotech 2008: the numbers. Nat Biotechnol 2009 Aug; 27 (8): 710-21
25. Lawrence S. Billion dollar babies: biotech drugs as blockbusters. Nat Biotechnol 2007 Apr; 25 (4): 380-382
26. Listing J, Strangfeld A, Kary S, et al. Infections in patients with rheumatoid arthritis treated with biologic agents. Arthritis Rheum 2005 Nov; 52 (11): 3403-3412
27. Strangfeld A, Listing J, Herzer P, et al. Risk of herpes zoster in patients with rheumatoid arthritis treated with anti- TNF-alpha agents. JAMA 2009 Feb; 301 (7): 737-744
28. Banks WA. Characteristics of compounds that cross the blood-brain barrier. BMC Neurol 2009 Feb; 9 Suppl. I: S3-7
29. Meyboom RH, Star K, Bate J, et al. TNF-a inhibitors and leukaemia: international pharmacovigilance reports. Drug Saf 2008 May; 31 (5): 445-447
30. Hamilton CD. Infectious complications of treatment with biologic agents. Curr Opin Rheumatol 2004 Jul; 16 (4): 393-398
31. Imperato AK, Smiles S, Abramson SB. Long-term risks associated with biologic response modifiers used in rheumatic diseases. Curr Opin Rheumatol 2004 May; 16 (3): 199-205
32. Boren EJ, Cheema GS, Naguwa SM, et al. The emergence of progressive multifocal leukoencephalopathy (PML) in rheumatic diseases. J Autoimmun 2008 Feb-Mar; 30 (1-2): 90-98
33. Leader B, Baca QJ, Golan DE. Protein therapeutics: a summary and pharmacological classification. Nat Rev Drug Discov 2008 Jan; 7 (1): 21-39
34. European Medicines Agency. European public assessment report MabThera [online]. Available from URL: http://www.emea.europa.eu/humandocs/PDFs/EPAR/ Mabthera/025998en6.pdf [Accessed 2009 Dec 22]
35. Noreán GB, Bate A. Johansson K. et al. Duplicate detection in the WHO adverse drug reaction database [online]. Available from URL: http://www.who-umc.org/graphics/9717.pdf [Accessed 2010 Apr 20]